AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease
Experimental Neurobiology
;
: 31-37, 2013.
Article
in English
| WPRIM
| ID: wpr-165484
ABSTRACT
Alzheimer's disease (AD) is a neurodegenerative disease that proceeds with the age-dependent neuronal loss, an irreversible event which causes severe cognitive and psychiatric devastations. In the present study, we investigated whether the compound, AAD-2004 [2-hydroxy-5-[2-(4-trifluoromethylphenyl)-ethylaminobenzoic acid] which has anti-oxidant and anti-inflammatory properties, is beneficial for the brain of Tg-betaCTF99/B6 mice, a murine AD model that was recently developed to display age-dependent neuronal loss and neuritic atrophy in the brain. Administration of AAD-2004 in Tg-betaCTF99/B6 mice from 10 months to 18 months of age completely repressed the accumulation of lipid peroxidation in the brain. AAD-2004 markedly suppressed neuronal loss and neuritic atrophy, and partially reversed depleted expression of calbindin in the brain of Tg-beta-CTF99/B6. These results suggest that AAD-2004 affords neurodegeneration in the brain of AD mouse model.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Atrophy
/
Brain
/
S100 Calcium Binding Protein G
/
Lipid Peroxidation
/
Aspirin
/
Neurodegenerative Diseases
/
Alzheimer Disease
/
Neurons
Limits:
Animals
Language:
English
Journal:
Experimental Neurobiology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS